Hydrochloric Acid

Hydrochloric Acid

SCHEMBL118624

Cl.Cl.N=C(N)NCCC[C@H](N)C(N)=O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 2/20 0.41
OTC P00480 1/20 0.40
NPY4R P50391 10/20 0.40
NPY1R P25929 6/20 0.40
NPY2R P49146 4/20 0.40
NPY5R Q15761 4/20 0.40
ALOX15 P16050 1/20 0.40
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
DDAH1 O94760 1/20 0.38
GNAI3 P08754 1/20 0.36
GNAO1 P09471 1/20 0.36
GNAI1 P63096 1/20 0.36
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1897057 1.00 DPP7 (0.41) DPP7OTCNPY4RNPY1RNPY2R
Hydrochloric Acid SCHEMBL29400705 1.00 DPP7 (0.41) DPP7OTCNPY4RNPY1RNPY2R
Hydrochloric Acid SCHEMBL7583819 1.00 DPP7 (0.41) DPP7OTCNPY4RNPY1RNPY2R
Hydrochloric Acid SCHEMBL14831575 1.00 DPP7 (0.41) DPP7OTCNPY4RNPY1RNPY2R
Hydrochloric Acid SCHEMBL123461 1.00 DPP7 (0.41) DPP7OTCNPY4RNPY1RNPY2R
Hydrochloric Acid SCHEMBL30600460 0.98 DPP7 (0.40) DPP7OTCNPY4RNPY1RNPY2R
SCHEMBL598710 0.98 DPP7 (0.42) DPP7OTCNPY4RNPY1RNPY2R
SCHEMBL304115 0.98 DPP7 (0.42) DPP7OTCNPY4RNPY1RNPY2R
SCHEMBL30256813 0.98 DPP7 (0.42) DPP7OTCNPY4RNPY1RNPY2R
SCHEMBL5158398 0.98 DPP7 (0.42) DPP7OTCNPY4RNPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224359-B1 ARGININE IMPROVES POLYMERASE STORAGE STABILITY BIO RAD LABORATORIES INC (US) 2023-10-25 EP claimed
CN-107875176-B Efficient propolis purification material 江山海维科技有限公司 2020-02-28 CN claimed
CN-107875176-A A kind of efficient propolis purification material 江山海维科技有限公司 2018-04-06 CN claimed
WO-2003056004-A1 IMPROVEMENTS IN ENZYME THERMOLABILITY UNISEARCH LIMITED (AU) 2003-07-10 WO claimed
WO-2003056001-A1 MODIFIED ENZYMES AND MODIFICATION PROCESSES UNISEARCH (AU) 2003-07-10 WO claimed
WO-2003056000-A1 MODIFIED ENZYME AND MODIFICATION PROCESS UNISEARCH (AU) 2003-07-10 WO claimed
WO-2003056002-A1 IMPROVEMENT IN AMYLASE STABILITY UNISEARCH LIMITED (AU) 2003-07-10 WO claimed
EP-4725960-A2 SWEET PROTEIN FROM TRUFFLE Mycotechnology, Inc. (US) 2026-04-15 EP disclosed
US-20260092310-A1 CAS12A COMPOSITIONS AND METHODS NEW ENGLAND BIOLABS, INC. (US) 2026-04-02 US disclosed
US-20260027071-A1 COMPOSITION FOR PROMOTING COLLAGEN PRODUCTION COMPRISING AMIDATED AMINO ACID KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND (KR) 2026-01-29 US disclosed
EP-4171199-B1 SWEET PROTEIN FROM TRUFFLE MYCOTECHNOLOGY INC (US) 2026-01-28 EP disclosed
EP-4661692-A2 HONEY TRUFFLE SWEETENER (HTS) VARIANTS Mycotechnology, Inc. (US) 2025-12-17 EP disclosed
US-12473250-B2 Molecular design of new antibiotics and antibiotic adjuvants against MCR strains SINGAPORE HEALTH SERVICES PTE LTD (SG) 2025-11-18 US disclosed
WO-2003056004-A1 IMPROVEMENTS IN ENZYME THERMOLABILITY UNISEARCH LIMITED (AU) 2003-07-10 WO disclosed
WO-2003056000-A1 MODIFIED ENZYME AND MODIFICATION PROCESS UNISEARCH (AU) 2003-07-10 WO disclosed
WO-2002098824-A2 IMPROVEMENTS IN ENZYME STABILITY UNISEARCH LIMITED (AU) 2002-12-12 WO disclosed
EP-1150946-A1 ARYLALKANOYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Aventis Pharma Deutschland GmbH (DE) 2001-11-07 EP disclosed
EP-1022268-A1 Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them Aventis Pharma Deutschland GmbH (DE) 2000-07-26 EP disclosed
WO-2000040548-A1 ARYLALKANOYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-07-13 WO disclosed
EP-0001774-A1 Derivatives of BPTI (basic pancreatic trypsin-inhibitor), process for their preparation and their use as medicines BAYER AG (DE) 1979-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092310-A1 CAS12A COMPOSITIONS AND METHODS RNASEL, RBM12, NT5C2 DPP7 2886/4885OTC 2035/4885NPY4R 4705/4885
US-20260027071-A1 COMPOSITION FOR PROMOTING COLLAGEN PRODUCTION COMPRISING AMIDATED AMINO ACID COL2A1, COL14A1, GLS DPP7 1389/4885OTC 478/4885NPY4R 738/4885
US-12473250-B2 Molecular design of new antibiotics and antibiotic adjuvants against MCR strains TLR5, TLR6, TLR4 DPP7 1077/4885OTC 1257/4885NPY4R 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.